These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11580969)

  • 1. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan.
    Yang WC; Hwang SJ; Chiang SS; Chen HF; Tsai ST
    Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S47-54. PubMed ID: 11580969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
    Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
    G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct costs-of-illness of patients with diabetes mellitus in Taiwan.
    Lin T; Chou P; Lai MS; Tsai ST; Tai TY
    Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S43-6. PubMed ID: 11580968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factor and cost accounting analysis for dialysis patients in Taiwan.
    Su BG; Tsai KL; Yeh SH; Ho YY; Liu SY; Rivers PA
    Health Serv Manage Res; 2010 May; 23(2):84-93. PubMed ID: 20424276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding cost of care for patients on renal replacement therapy: looking beyond fixed tariffs.
    Li B; Cairns JA; Fotheringham J; Tomson CR; Forsythe JL; Watson C; Metcalfe W; Fogarty DG; Draper H; Oniscu GC; Dudley C; Johnson RJ; Roderick P; Leydon G; Bradley JA; Ravanan R
    Nephrol Dial Transplant; 2015 Oct; 30(10):1726-34. PubMed ID: 26071229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growing economic burden of diabetic kidney disease.
    Foley RN; Collins AJ
    Curr Diab Rep; 2009 Dec; 9(6):460-5. PubMed ID: 19954692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic challenges in the management of diabetic nephropathy.
    Rodby RA
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S6-11. PubMed ID: 15369419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Higher Quality of Care on Initiation of Long-term Dialysis in Patients With CKD and Diabetes.
    Wu HY; Fukuma S; Shimizu S; Norton EC; Tu YK; Hung KY; Chen MR; Chien KL; Fukuhara S
    Am J Kidney Dis; 2017 Nov; 70(5):666-674. PubMed ID: 28764919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Year Outcomes of Early Cannulation Arteriovenous Grafts for End-Stage Renal Disease.
    Desai SS
    Ann Vasc Surg; 2019 Aug; 59():158-166. PubMed ID: 31009720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.